Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Capstone Therapeutics ( (CAPS) ).
At its November 18, 2025 annual meeting, Capstone Holding Corp. shareholders unaffiliated with Nectarine Management LLC approved a letter agreement authorizing consent fees to Nectarine—owned by four Capstone directors and controlling the company’s Series B preferred stock—in return for its support on major corporate transactions such as mergers, significant asset deals, stock issuances, joint ventures and new debt. Following the December 1, 2025 acquisition of Fraser Canyon Holdings Inc., the board’s Nominating and Corporate Governance Committee on December 19, 2025 approved about $88,700 in fees and up to $50,000 in legal cost reimbursement to Nectarine tied to the cash portion of the deal, with additional contingent payments to Nectarine’s principals dependent on repayment of a CAD$3.6 million seller note and a CAD$3 million earn‑out, while subsidiary TotalStone, LLC simultaneously secured an extension of its $8.3 million revolving credit facility with Berkshire Bank to June 19, 2026, supporting ongoing liquidity and growth plans.
The most recent analyst rating on (CAPS) stock is a Hold with a $0.69 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics’ overall stock score reflects significant financial challenges, including declining revenue and negative equity, which weigh heavily on the score. While technical indicators are bearish, recent corporate events provide a positive outlook with strategic acquisitions and growth plans. However, the negative valuation metrics further dampen the overall score.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Capstone Holding Corp., parent of building materials distributor TotalStone, operates through subsidiaries including Canadian Stone Industries following its December 1, 2025 acquisition of Fraser Canyon Holdings Inc., focusing on stone and related construction products in North America.
Average Trading Volume: 755,761
Technical Sentiment Signal: Sell
Current Market Cap: $5.85M
For detailed information about CAPS stock, go to TipRanks’ Stock Analysis page.